Serenity Bioworks Inc.

5 enregistrements totalisant 251,037.00 $ CAN, selon les données ouvertes officielles du gouvernement du Canada.

Intégrer ce graphique

Par ministère

Conseil national de recherches Canada $251,037 5 enregistrements

Enregistrements

Serenity Bioworks Inc. $90,000.00
National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
EF 2021-2022
Canada

Serenity Bioworks is conducting drug-development studies to gain a better understanding of the interaction and effectiveness of its lead biotherapeutic in combination with the standard of care drugs i...

Serenity Bioworks Inc. $50,000.00
National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
EF 2020-2021
Canada

Serenity Bioworks is conducting a feasibility study to produce the second-generation biotherapeutics for the treatment of autoimmune diseases with unmet medical needs.

Serenity Bioworks Inc. $48,705.00
National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Innovation Assistance Program
EF 2020-2021
Canada

The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support

Serenity Bioworks Inc. $40,656.00
National Research Council Canada | Conseil national de recherches Canada
Innovation Assistance Program
EF 2020-2021
Canada

The funding provided by the IAP program is intended to assist innovative small and medium-sized enterprises in the start-up phase that cannot access existing commercial support related to COVID-19.

Serenity Bioworks Inc. $21,676.00
National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Innovation Assistance Program
EF 2020-2021
Canada

The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.